Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000STRA555
Wed, 07.06.2023
STRATEC SE
STRATEC FURTHER EXPANDS ITS PRESENCE IN USA BY ACQUIRING NATECH PLASTICS
Acquisition of smart polymer-based consumables provider focused on medical applications
The addition of a local production site will extend STRATEC’s focus on the US market
Diversification due to high share of recurring sales, extended customer base, and complementary tar [ … ]
Wed, 17.05.2023
STRATEC SE
STRATEC’S ANNUAL GENERAL MEETING APPROVES FURTHER DIVIDEND INCREASE: DISTRIBUTION RISES TO € 0.97 PER SHARE
Birkenfeld, May 17, 2023
Shareholders at today’s Annual General Meeting of STRATEC SE (Frankfurt: SBS; Prime Standard, SDAX) approved all agenda items submitted for resolution with clear majorities. As in the past three years, the Annual G [ … ]
Wed, 17.05.2023
STRATEC SE
STRATEC’S ANNUAL GENERAL MEETING APPROVES FURTHER DIVIDEND INCREASE: DISTRIBUTION RISES TO € 0.97 PER SHARE
Birkenfeld, May 17, 2023
Shareholders at today’s Annual General Meeting of STRATEC SE (Frankfurt: SBS; Prime Standard, SDAX) approved all agenda items submitted for resolution with clear majorities. As in the past three years, the Annual G [ … ]
Fri, 28.04.2023
STRATEC SE
STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2023 AND CONFIRMS FINANCIAL GUIDANCE
Sales in Q1/2023 -19.8% to € 60.5 million; constant-currency -20.7% (Q1/2022: € 75.4 million)
Adjusted EBIT margin of 6.3% in Q1/2023 as expected below previous year (Q1/2022: 19.9%)
2023 guidance confirmed: Constant-currency sales growth of 8.0% to 12.0% and adjuste [ … ]
Fri, 28.04.2023
STRATEC SE
STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2023 AND CONFIRMS FINANCIAL GUIDANCE
Sales in Q1/2023 -19.8% to € 60.5 million; constant-currency -20.7% (Q1/2022: € 75.4 million)
Adjusted EBIT margin of 6.3% in Q1/2023 as expected below previous year (Q1/2022: 19.9%)
2023 guidance confirmed: Constant-currency sales growth of 8.0% to 12.0% and adjuste [ … ]
Thu, 30.03.2023
STRATEC SE
STRATEC REPORTS FINAL FIGURES FOR 2022 FINANCIAL YEAR
Consolidated sales in 2022 -4.4% to € 274.6 million (2021: € 287.3 million);
constant-currency: -8.3%
Adjusted EBIT margin of 16.4% (2021: 18.9%) broadly in line with original expectations
Major product launch for one of the market leaders in molecular diagnostics and
a well-stocked develo [ … ]
Thu, 30.03.2023
STRATEC SE
STRATEC REPORTS FINAL FIGURES FOR 2022 FINANCIAL YEAR
Consolidated sales in 2022 -4.4% to € 274.6 million (2021: € 287.3 million);
constant-currency: -8.3%
Adjusted EBIT margin of 16.4% (2021: 18.9%) broadly in line with original expectations
Major product launch for one of the market leaders in molecular diagnostics and
a well-stocked develo [ … ]
Thu, 09.03.2023
STRATEC SE
STRATEC REPORTS PRELIMINARY RESULTS FOR 2022 FINANCIAL YEAR AND ISSUES FINANCIAL GUIDANCE FOR 2023
Birkenfeld, March 9, 2023
Based on preliminary figures, STRATEC expects to report consolidated sales of € 274.6 million for the 2022 financial year (2021: € 287.3 million). This corresponds to a year-on-year reduction in sales by 4.4% (constant curr [ … ]
Thu, 09.03.2023
STRATEC SE
STRATEC REPORTS PRELIMINARY RESULTS FOR 2022 FINANCIAL YEAR AND ISSUES FINANCIAL GUIDANCE FOR 2023
Birkenfeld, March 9, 2023
Based on preliminary figures, STRATEC expects to report consolidated sales of € 274.6 million for the 2022 financial year (2021: € 287.3 million). This corresponds to a year-on-year reduction in sales by 4.4% (constant curr [ … ]
Thu, 15.12.2022
STRATEC SE
STRATEC TO PARTICIPATE IN THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Birkenfeld, December 15, 2022
STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at the Westin St. Francis in San Francisco, CA, USA. Marcus Wolfing [ … ]